May 13 |
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
|
May 13 |
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
|
May 13 |
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
May 10 |
Catalyst's New CEO Has Big Ideas For The Small Biotech
|
May 10 |
Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
|
May 9 |
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
|
May 9 |
Takeda tackles $900m restructuring plan after generics hurt annual profits
|
May 9 |
Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation
|
May 9 |
Takeda seeks efficiency as operating profit slumps
|
May 9 |
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
|